---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-123274"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2023-12-04T23:59:59+00:00"
generated_at: "2026-06-07T18:52:21.286438+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics raises $1.21M in registered direct offering of 5M shares at $0.242/share

## Summary
- Sold 5,000,000 shares of common stock at $0.242 per share, gross proceeds of $1.21 million.
- Offering closed on December 4, 2023; H.C. Wainwright & Co. acted as exclusive placement agent.
- Placement agent received warrants to purchase 300,000 shares at $0.3025 per share, exercisable for 5 years.
- Net proceeds will fund clinical trials for lead candidate TTX-MC138 and for working capital.

## SEC filing metadata
- accession: 0001104659-23-123274
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2023-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465923123274/0001104659-23-123274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465923123274/tm2332042d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-123274
- JSON: https://secwatch.observer/filing/0001104659-23-123274.json
- Plain text: https://secwatch.observer/filing/0001104659-23-123274.txt

## Key facts
- Material Agreements
  Transcode Therapeutics, Inc. entered into Securities Purchase Agreement with institutional investors named therein valued at $1.21 million (effective 2023-11-30).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: institutional investors named therein
  - Value: $1.21 million
  - Effective: 2023-11-30
  source text: On November 30, 2023, TransCode Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), an aggregate of 5,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at an offering price of $0.242 per share of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465923123274/0001104659-23-123274-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.